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ABSTRACT 
Multiple potentially harmful stimuli challenge the liver, the chief metabolic and detoxifying 
organ of the human body. Due to its central anatomical location, continuous blood flow from 
the gastrointestinal tract through the hepatic sinusoids allows the metabolically active hepato-
cytes, the non-parenchymal cells and the various immune cell populations residing and patrol-
ling in the liver to interact with antigens and microbiological components coming from the in-
testine. Cytokines are key mediators within the complex interplay of intrahepatic immune 
cells and hepatocytes, because they can activate effector functions of immune cells as well as 
hepatocytic intracellular signaling pathways controlling cellular homeostasis. Kupffer cells 
and liver-infiltrating monocyte-derived macrophages are primary sources of cytokines such as 
tumor necrosis factor (TNF). The liver is also enriched in natural killer (NK) and natural killer 
T (NKT) cells, which fulfill functions in pathogen defense, T cell recruitment and modulation 
of fibrogenic responses. TNF can activate specific intracellular pathways in hepatocytes that 
influence cell fate in different manners, e.g. pro-apoptotic signals via the caspase cascade, but 
also survival pathways, namely the nuclear factor (NF)-kappaB pathway. NF-kappaB regu-
lates important functions in liver physiology and pathology. The exact dissection of the con-
tribution of recruited and resident immune cells, their soluble cytokine and chemokine media-
tors and the intracellular hepatocytic response in liver homeostasis and injury could potential-
ly identify novel targets for the treatment of acute and chronic liver disease, liver fibrosis or 
cirrhosis. 
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INTRODUCTION 
The human liver unites a bandwidth of 
purposes like metabolic, synthetic and de-
toxifying functions. Its exceptional role for 
regulating body’s homeostasis is challenged 
by liver diseases, whose incidence is in-
creasing globally and which represent an 
outstanding challenge in health care world-
wide. While the main causes of liver dis-
ease in the Western world are non-alcoholic 
steatohepatitis (NASH), alcohol and chron-
ic hepatitis C infections, chronic hepatitis B 
and C infections are major reasons for liver 
disease in the Middle East and Asia. De-
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spite different origins of liver injury, virtu-
ally all liver diseases trigger specific in-
flammatory processes, which eventually 
promote tissue loss, aberrant wound healing 
resulting in liver fibrosis, cirrhosis as an 
end-stage and occurrence of hepatocellular 
carcinoma (Bataller and Brenner, 2005).  
The activation of inflammatory path-
ways is not necessarily harmful in all cir-
cumstances. For instance, the liver has also 
the unique potential to regenerate after tis-
sue loss (a process, which is regulated by 
inflammatory mediators) and plays an im-
portant role in regulating blood glucose or 
blood lipid levels in response to the current 
demand of the body (e.g., in conditions of 
inflammation). The central function of the 
liver for homeostasis and inflammatory re-
sponses is also underscored by its sole ana-
tomical location, allowing continuous blood 
supply not only from the arterial system 
(hepatic arteries) but also from the gastroin-
testinal tract via the portal vein (Figure 1). 
Circulating blood cells, e.g. from the innate 
or adaptive immune system, are passing a 
network of sinusoids allowing contact to a 
variety of intrahepatic cell populations such 
as parenchymal liver cells (hepatocytes), 
endothelial cells, liver-resident macrophag-
es (Kupffer cells) or lymphocyte (e.g., NKT 
cells) populations, hepatic stellate cells and 
others (Figure 1) (Racanelli and Reher-
mann, 2006). 
Communication between these cell 
types and the regulation of hepatic func-
tions are greatly facilitated by cytokines. 
Cytokines are small molecular weight mes-
sengers secreted by one cell to alter the be-
havior of the cell itself (autocrine messen-
ger), a closely related cell (paracrine mes-
senger) or cells in different organs (endo-
crine messenger) (Luedde et al., 2002).  
 
INTRAHEPATIC IMMUNE CELLS  
AS PRODUCERS AND TARGETS  
OF CYTOKINES 
Besides its various metabolic functions, 
the liver may be also viewed as a central 
immunological organ of the human body. It 
receives blood coming from the gastrointes-
tinal tract through the portal vain, which is 
enriched with potential antigens and micro-
organisms. Immune cells in the liver have 
the potential to initiate both: a) innate and 
adaptive immune responses in the case of 
infections, e.g. in response to lipopolysac-
charide (LPS) or bacterial superantigens, or 
b) immunological tolerance in the vast ma-
jority of harmless antigens during homeo-
stasis (Tacke et al., 2009).  
 
 
 
Figure 1: Intrahepatic cell populations. The healthy liver comprises about 60-80 % hepatocytes; the 
other intrahepatic cell populations include biliary epithelial cells (cholangiocytes), liver sinusoidal endo-
thelial cells (LSECs) lining the liver sinusoids, Kupffer cells (KC), and hepatic stellate cells (HSC) in 
the Dissé space between hepatocytes and LSECs. In addition, many immune cells are found in the 
liver, mainly entering from the circulation via hepatic arteries and portal vein branches, including neu-
trophils (PMN), monocytes (monos), dendritic cells (DCs) and lymphocytes (T, B, NK, NKT cells). 
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Innate immunity within the liver  
The liver is especially enriched in mac-
rophages (Kupffer cells), natural killer 
(NK) and natural killer T (NKT) cells. Alt-
hough it has been long known that Kupffer 
cells can principally originate from bone-
marrow-derived monocytes (Luedde et al., 
2002), Kupffer cells have long been consid-
ered a rather sessile, tissue-resident and 
(fairly) radio-resistant population (Naito et 
al., 1997; Duffield et al., 2005). Experi-
mental data have challenged this concept, 
as mouse models revealed that approxi-
mately half of the Kupffer cells in a steady 
state liver may originate directly from 
bone-marrow precursors, indicating a high 
turnover rate of macrophages in liver ho-
meostasis (Klein et al., 2007). Nevertheless, 
using sophisticated cell tracking techniques 
in mice, recent experiments revealed that 
the majority of Kupffer cells in homeostasis 
delineate from local precursors and con-
stantly renew themselves dependent on the 
growth factors GM-CSF and M-CSF (Yona 
et al., 2013). In the case of inflammation, 
blood-derived infiltrating monocytes are at-
tracted to the injured liver, activated by cer-
tain cytokines and become dominant for 
macrophage actions, as suggested by ani-
mal models of chronic liver injury and fi-
brogenesis (Duffield et al., 2005; Imamura 
et al., 2005). Monocytes consist of at least 
two major subsets with different migratory 
and functional properties (Tacke and 
Randolph, 2006; Tacke et al.; 2007, Tacke 
et al., 2006); their specific roles in liver 
homeostasis, inflammation and regression 
are the subject of intensive ongoing re-
search. 
 
Natural killer (NK) cells in liver homeo-
stasis and injury  
NK cells represent a population of lym-
phocytes with potent cytolytic activity 
against virus-infected or tumor cells. Hepat-
ic NK cells are regulated by, for example, 
Kupffer-cell derived cytokines, like IL-12 
and IL-18, as well as IL-4 driven by NKT 
cells (Wehr et al., 2013). Hepatic NK cells 
produce large amounts of interferon gamma 
(IFN) upon activation (Figure 2), and 
modulate T cell responses in the liver, pro-
mote intracellular changes in endothelial 
cells as well as hepatocytes (mainly via 
IFN) and can even directly promote 
necroptosis of hepatocytes or cell lysis 
(Dong et al., 2007; Bilzer et al., 2006; 
Fallowfield et al., 2007). In chronic in-
flammatory conditions, e.g. chronic hepati-
tis B virus infection, liver injury is closely 
linked to NK-mediated IL-8 and IFN syn-
thesis as well as accumulation and activa-
tion of NK cells in the liver expressing the 
apoptosis-inducing TNF-related apoptosis 
ligand (TRAIL) (Dunn et al., 2007). 
In humans an increase of CD16- NK 
cells in blood and CD16+ NK cell subset in 
liver are closely associated with liver-disea-
se severity and hepatofibrogenesis (Zim-
mermann et al., 2013). Furthermore, pa-
tients suffering from chronic liver diseases 
show elevated IL-8 serum levels, according 
to raised IL-8 producing NK cell popula-
tions, which is associated with a hepatic 
macrophage accumulation via the IL-8 re-
ceptor CXCR1 (Zimmermann et al., 2011; 
Tacke et al., 2011) and may promote profi-
brogenic responses. 
 
Macrophages in liver homeostasis and in-
jury 
While Kupffer cells are important for 
sensing liver injury and initiating inflamma-
tion, infiltrating liver-macrophages (iMϕ) 
have the capacity to phagocytize and re-
lease a broad panel of cytokines, which crit-
ically determine the subsequent reactions of 
other immune cells and hepatocytes as well 
as the degree of fibrosis by activating myo-
fibroblasts (Bilzer et al., 2006). Depending 
on their differentiation (classically activated 
Ly-6Chi vs. alternatively activated Ly-6Clo) 
iMϕ release a variety of proinflammatory 
cytokines such as tumor-necrosis factor 
(TNF), IL-6, IL-1 or leukotrienes (Ly-6Chi 
iMϕ) (Figure 2) (Luedde et al., 2002); or in 
the context of low “physiological” levels of 
LPS or during liver damage regression, also 
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anti-inflammatory cytokines like IL-10 and 
MMP9/12/13 (Ly-6Clo iMϕ) (Knolle, 2006; 
Baeck et al., 2012). In acute or chronic liver 
diseases, Kupffer cells and infiltrating 
monocyte-derived macrophages are known 
to promote inflammatory cascades by re-
leasing these proinflammatory mediators 
with consequences for T cell attraction, 
NKT cell activation, induction of hepato-
cyte apoptosis (Figure 2) or activation of fi-
brogenic hepatic stellate cells (HSC) (Bilzer 
et al., 2006; Schumann et al., 2000; Wehr et 
al., 2013). 
Chemokines, on the other hand, critical-
ly control the infiltration of macrophages 
upon liver injury and thereby promote he-
patic inflammation and fibrosis. Chemokine 
receptors like the C-C motif chemokine re-
ceptor 2 (CCR2) and CCR8 can affect traf-
ficking of monocytes/macrophages, DCs 
and T-helper cells into the liver and are crit-
ical for inducing liver-fibrosis as well as re-
generation depending on the time point of 
secretion and the stage of liver disease 
(Baeck et al., 2012; Heymann et al., 2012; 
Zimmermann et al., 2012; Zimmermann 
and Tacke, 2011). Murine models revealed 
that early inflammatory Ly-6Chi iMϕ infil-
trate the acutely injured liver, dependent on 
chemotaxis through chemokine – receptor 
interactions CCL2 - CCR2 or CCL1 - 
CCR8 (Galastri et al., 2012, Heymann et 
al., 2012, Karlmark et al., 2009, Miura et 
al., 2012). After infiltration, these Ly-6Chi 
iMϕ activate HSC and favor their transdif-
ferentiation to myofibroblasts, which leads 
to enhanced collagen production and scar 
formation (Baeck et al., 2012; Seki et al., 
2007; Fallowfield et al., 2007). 
As mentioned above, alternatively acti-
vated Ly-6Clo iMϕ appear to constitute key 
players in regeneration of liver fibrosis and 
liver injury regression. Recent studies 
showed that these matured macrophages re-
duced liver scarring by attracting anti-
fibrotic and collagen-degrading immune 
cells resulting into enhanced levels of anti-
fibrotic IL-10 and increased metallopro-
teinases MMP-9 and -13 activation (Baeck 
 
Figure 2: Selected key interactions between 
innate immune cells and hepatocytes. Kup-
ffer cells (macrophages), NKT and NK cells are 
abundantly found in the liver. Kupffer cells (KC) 
can release IL-6 and TNF, activating hepato-
cytic gp130-dependent STAT signaling cas-
cades and TNF-R dependent activation of 
apoptotic caspase and/or anti-apoptotic (pro-
inflammatory) NF-kappaB (NFκB) pathways. 
NKT cells exert their actions via release of TNF, 
IFN or FasL-mediated apoptosis. NK cells can 
also release IFN and may induce apoptosis via 
TRAIL in the case of hepatocytic TRAIL-R ex-
pression. 
 
et al., 2013; Thomas et al., 2011; Imamura 
et al., 2005). Furthermore, recent murine 
investigations showed significantly en-
hanced liver regeneration from fibrosis by 
pharmacological augmenting the number of 
Ly-6Clo iMϕ during wound healing (Baeck 
et al., 2013). 
 
NKT cells in liver homeostasis and injury 
NKT cells are a heterogeneous popula-
tion of unconventional T cells that express 
markers of NK cells and T cell receptors 
(TCRs). NKT cells are found at remarkably 
high numbers in the liver. From studies of 
experimental liver injury in mice after ad-
ministration of the plant-derived lectin 
Concanavalin A (ConA), NKT cells have 
been identified as critical factors promoting 
acute liver damage by release of IL-4, IFN 
and direct induction of Fas-mediated 
hepatocyte apoptosis (Figure 2) (Tiegs, 
2007). NKT subsets with different func-
tions exist in humans and mice: classical 
(type I) invariant (iNKT), other CD1d-
dependent (type II) NKT cells, as well as 
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CD1d-independent (NKT-like) T cells 
(Wehr et al., 2013). However, the physio-
logical function of the individual subsets is 
basis of current investigations. Recent stud-
ies revealed an important role of NKT cells 
in the development of liver fibrosis in mice 
by accentuating the inflammatory process 
and activating pro-fibrogenic macrophages 
through the release of cytokines (Kinjo et 
al., 2005; Mattner et al., 2005; Wehr et al., 
2013). Furthermore, NKT cells are involved 
in antiviral defense mechanisms by secret-
ing IFN, e.g. during chronic hepatitis B vi-
rus infection as suggested by studies in 
transgenic mice (Kakimi et al., 2000).  
 
Antigen presenting cells and adaptive im-
mune cells in the liver 
For the initiation of adaptive immune 
responses, antigens need to be processed 
and professionally presented to T cells, ei-
ther in the liver itself or in the draining 
lymph nodes (Racanelli and Rehermann, 
2006). Several hepatic cell populations 
have antigen-presenting properties. In non-
inflammatory conditions, antigen-presen-
tation by liver sinusoidal endothelial cells 
appears to be a crucial mechanism for the 
maintenance of immunological tolerance 
(Limmer et al., 2000). Furthermore, Kup-
ffer cells and also bone-marrow derived 
dendritic cells, mostly of monocytic origin 
linking the innate and adaptive part of im-
mune responses, can efficiently prime T 
cells (Bilzer et al., 2006; Racanelli and 
Rehermann, 2006; Tacke and Yoneyama, 
2013). The nature of the T cell response, 
e.g. T-cell cytotoxicity in the case of a 
chronic viral infection or T-cell tolerance in 
the case of harmless gut-derived antigens or 
autoantigens, seems to depend on the anti-
gen-presenting cells, the cytokine milieu 
and the site of primary T cell activation 
(Bowen et al., 2004; Crispe et al., 2006). 
HSCs, known for vitamin A storage and 
collagen synthesis in liver-fibrosis (as acti-
vated myofibroblasts), have been suggested 
as cells with antigen-presenting capacity it-
self that can activate T cell responses, e.g. 
after bacterial challenge (Winau et al., 
2007; Nevzorova et al., 2012) 
The liver is also one of the richest 
sources of γδ T-cells in the body, which are 
an unconventional (or innate) T-cell subset 
that expresses the γδ TCR. These IL-17 and 
IL-22 expressing γδ T-cells are recruited to 
the liver via chemokine-chemokine receptor 
activation (CCL20-CCR6) upon chronic in-
jury and were shown to protect the liver 
from excessive inflammation and fibrosis 
by inhibiting HSC (Hammerich et al., 2014; 
2011). 
 
 
 
Figure 3: Macrophage subsets in chronic 
liver injury. In the acute phase of hepatic injury 
increased levels of CCL2 and CCL1 activates 
‘classical’ Ly-6Chi monocytes via their receptors 
that enter the liver, where they develop into infil-
trating Ly-6Chi macrophages exhibiting a pro-
inflammatory phenotype, which partly resem-
bles M1 macrophages. These macrophages 
support the progression of chronic liver injury 
and fibrosis through TGF-β/PDGF-mediated 
HSC transdifferentiation, activation and prolifer-
ation. This leads to the accumulation of colla-
gen resulting in fibrosis of the organ. After mat-
uration from Ly-6Chi to Ly-6Clo macrophages, 
these cells can adopt a restorative phenotype 
characterized by Ly-6Clo expression and capac-
ity to degrade excessive extracellular matrix 
proteins via metalloproteinases (MMP-9,-12) 
and to induce HSC apoptosis during fibrosis 
resolution. 
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TNF AND THE TNF-RECEPTOR  
IN THE LIVER 
Besides direct effects of immune cells 
on hepatocytes and other liver cells, in-
flammatory processes in the liver are large-
ly regulated by cytokines. Cytokine action 
is generally mediated by the interaction of 
cellular receptors with their ligand. These 
networks have evolved early in the evolu-
tion; pathways with strong homology to 
human cytokine networks are already found 
in Drosophila and mollusks (Luedde and 
Trautwein, 2006). E.g. in Drosophila, Nu-
clear Factor (NF)-kappaB-like transcription 
factors are activated in order to combat in-
fections; this still represents one major role 
of cytokine networks in higher organisms 
like humans. Maintaining the ordered bal-
ance between proliferation and controlled 
cell death (apoptosis) during embryonic de-
velopment and organogenesis is another 
important function of cytokines in physio-
logic conditions. The stability of the cyto-
kine relation to each other is essential for 
stable conditions of immune cell response 
within an organ (Luedde et al., 2002). 
Dysregulated cytokine actions after liver in-
jury, for example, can result in excessive 
apoptosis, a key finding in various acute 
and chronic liver diseases, e.g. viral and au-
toimmune hepatitis, cholestatic disease, al-
coholic or drug/toxin-induced liver injury 
(Neuman, 2001). Among the manifold cy-
tokines relevant for liver homeostasis and 
injury, we will highlight important findings 
on TNF as a represent pathway with excep-
tional significance in the liver. Studies in 
patients and animal models have strongly 
implicated that death receptor ligands such 
as TNF or Fas ligand (FasL) are involved in 
the induction of apoptosis / necroptosis and 
in triggering destruction of the liver (Streetz 
et al., 2000a), which leads to final organ 
failure like liver-fibrosis. 
TNF and FasL belongs to a family of 
nine ligands (TNF, lymphotoxin-, TNF, 
FasL, OX40L, CD40L, CD27L, CD30L, 4-
1BBL and lymphotoxin-) that activate 
structurally related receptor proteins known 
as the TNF receptor superfamily. Currently, 
twelve different death receptors are well es-
tablished including TNF receptor 1 (TNF-
R1, Figure 4), TNF-R2, TNF-RP, Fas, OX-
40, 4-1BB, CD40, CD30, CD27, pox virus 
PV-T2, PV-A53R gene products, and the 
p75 NGFR. In addition, the apoptosis-
signaling receptors death receptor 3 (DR3), 
DR4 and DR5, their ligand TRAIL, and a 
nonsignaling decoy receptor TRID/DcR are 
recently identified members of these super-
families (Schulze-Osthoff et al., 1998; 
Tacke et al., 2009). In patients with fulmi-
nant hepatic failure, serum levels of TNF, 
TNF-R1 and TNF-R2 are markedly in-
creased and these changes directly correlat-
ed with disease activity. However, in liver 
physiology the TNF-R1 plays a predomi-
nant role (Streetz et al., 2000b; 2003). 
 
The intracellular TNF pathway in liver 
homeostasis and inflammation 
In many instances, hepatic failure might 
result from an imbalance between damag-
ing and protective signals that are very 
tightly regulated under physiologic condi-
tions. As mentioned above, TNF and relat-
ed cytokines are key players in liver home-
ostasis as they can activate both, pro-
apoptotic (mainly caspases) and anti-
apoptotic (mainly NF-kappaB) pathways in 
hepatocytes (Figure 4) (Ghosh and Karin, 
2002; Liedtke and Trautwein, 2012; Rao et 
al., 2010, Rothwarf et al., 1998). 
 
Activation of pro-apoptotic signaling cas-
cades 
FasL and TNF facilitate programmed 
cell death in a similar manner by activation 
of caspases. The most important target of 
both pathways orchestrating cellular death 
is the aspartate-specific cysteine protease- 
or caspase-cascade, consisting of initiator 
caspases such as caspases 8 and 9 and exe-
cutioner caspases, e.g. caspase 3, 6 and 7. 
Since proteolytic cleavage generates the 
mature caspases, one way by which these 
enzymes are activated is via the action of 
proteases, including other caspases (Martin 
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and Green, 1995). TNF signals through two 
distinct cell surface receptors, TNF-R1 and 
TNF-R2, of which TNF-R1 initiates the 
majority of TNF’s biological activities. 
Binding of TNF to its receptor leads to the 
recruitment of the inhibitory protein silenc-
er of death domains (SODD) from TNF-
R1’s intracellular domain. This results in 
the activation of the adaptor protein TNF 
receptor associated death domain 
(TRADD), the central molecule of the TNF 
signaling, which in turn recruits Fas-
associated death domain (FADD). FADD 
recruits caspase-8 to the TNF-R1 complex, 
where it becomes activated and initiates the 
protease cascade leading to activation of 
executioner caspases and apoptosis (Figure 
4) (Chen and Goeddel, 2002; Cubero et al., 
2013; Das et al., 2009). 
 
 
Figure 4: TNF signaling in the liver. TNF- binds to its receptors, e.g. TNF-R1, and can thereby acti-
vate the proapoptotic caspase cascades (via TRADD, FADD and cleavage of pro-caspase 8) or the 
anti-apoptotic NF-kappaB pathway (via activation of the IKK-complex resulting in phosphorylation of 
IkBalpha, subsequent translocation of NF-kappaB to the nucleus and expression of NF-kappaB re-
sponsive genes). For details, please see main text. 
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In hepatocytes, caspase-8-mediated sig-
nals are also influenced by a mitochondrial 
pathway: The cytosolic protein Bid (BH3- 
interacting domain death agonist) is proteo-
lytically activated by caspase-8 and thereby 
converted into its active form tBID which 
translocates into the mitochondrial mem-
brane and contributes to increased mito-
chondrial permeability and subsequent to 
release cytochrome C from the mitochon-
dria into the cytosol via the membrane pro-
teins Bax and Bac. The release of cyto-
chrome C triggers the activation of caspase-
3 via caspase-9. Via positive feedback 
loops, caspase-3 may then activate further 
procaspase-8 molecules, but also directly 
triggers necroptosis (Liedtke et al., 2011; 
Ashkenazi and Dixit, 1998; Streetz et al., 
2000a; Gupta et al., 2005). Interestingly, 
caspase-8 has two faces within liver home-
ostasis: mice with hepatocellular deletion of 
caspase-8 were protected against liver inju-
ry and hepatocarcinogenesis, while caspase-
8-deficient immune cells were responsible 
for increased liver injury in models of cho-
lestatic hepatitis (Chaudhary et al., 2013; 
Liedtke et al., 2011). 
In contrast to TNF-dependent signaling, 
FasL can interact directly with the death 
domain of FADD without recruiting 
TRADD (Ashkenazi and Dixit, 1998; Chen 
and Goeddel, 2002). 
 
Activation of the NF-kappaB pathway 
In addition the activation of caspases, 
binding of TNF to its receptor also leads to 
the activation of the NF-kappaB pathway 
(Figure 4). NF-kappaB is a heterodimer or a 
homodimer of members of the Rel family 
of DNA-binding proteins, and regulates the 
transcription of genes that contain kappaB 
binding sites. The mammalian NF-kappaB 
family includes five cellular DNA-binding 
subunits: p50 (NF-κB1), p52 (NF-κB2), c-
Rel (Rel), p65 (RelA) and RelB (Ghosh et 
al., 1998). The N-terminal Rel homology 
domain (RHD), which is shared by NF-
kappaB DNA-binding subunits, is responsi-
ble for DNA-binding, dimerization, nuclear 
translocation and interaction with the inhib-
itory I-kappaB proteins. In addition, p65, 
RelB and cRel contain a C-terminal trans-
activation domain, which activates tran-
scription (Ghosh and Karin, 2002). NF-
kappaB leads to different gene transcription 
with kappaB binding sites within the liver, 
which are involved in the regulation of in-
flammation, cell survival and immune re-
sponse (Pahl, 1999). 
In the liver, NF-kappaB mediates pro-
tective and anti-apoptotic effects. Thus, 
hepatocytes with a specific deletion for the 
adapter molecule NEMO that abrogates 
NF-kappaB activation, are hypersensitive 
for massive TNF-induced apoptosis in vivo 
and in vitro (Beraza et al., 2007). 
TNF-induced activation of NF-kappaB 
relies on the phosphorylation of two con-
served serines (S32 and S36 in human I-
kappaB) in the N-terminal regulatory do-
main of I-kappaBs. After phosphorylation, 
the I-kappaBs undergo a second post-
translational modification: polyubiquitina-
tion by a cascade of enzymatic reactions, 
followed by the degradation of IB proteins 
by the proteasome, thus releasing NF-
kappaB from its inhibitory I-kappaB-
binding partner, so it can translocate to the 
nucleus and activate transcription of NF-
kappaB dependent target genes (Figure 4) 
(Beraza et al., 2007; Karin, 1999; Yamamo-
to and Gaynor, 2004). Since the enzymes 
that catalyze the ubiquitination of I-kappaB 
are constitutively active, the only regulated 
step in NF-kappaB activation appears to be 
in most cases the phosphorylation of I-
kappaB molecules (Liedtke and Trautwein, 
2012).  
The high-molecular-weight “IKK-com-
plex” mediates the phosphorylation of I-B 
(Figure 4). This complex consists of three 
tightly associated I-B kinase (IKK) poly-
peptides: IKK1 (also called IKK) and 
IKK2 (IKK), the catalytic subunits of the 
kinase complex (DiDonato et al., 1997; 
Mercurio et al., 1999; Regnier et al., 1997), 
and a regulatory subunit called NEMO 
(NF-kappaB Essential Modulator, IKK) 
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(Mercurio et al., 1999; Rothwarf et al., 
1998). In vitro, IKK1 and IKK2 can form 
homo- and heterodimers (Zandi et al., 
1998). Both IKK1 and IKK2 are able to 
phosphorylate I-κB in vitro, but IKK2 has a 
higher kinase activity in vitro compared 
with IKK1 (Delhase et al., 1999; Mercurio 
et al., 1999; 1997; Woronicz et al., 1997; 
Zandi et al., 1997). 
Activation of the IKK complex upon 
TNF stimulation involves IKK recruitment 
to the TNF-R1 (Devin et al., 2000; 2001, 
Zhang et al., 2000). Besides TNF-R1, this 
process involves TNF-receptor-associated-
factor 2 (TRAF2) and the death-domain ki-
nase receptor-interacting protein (RIP). Af-
ter TNF treatment, TRAF2 recruits the 
IKK-complex to TNF-R1 via the interaction 
of the RING-finger motifs of TRAF2 with 
the leucin-zipper motif of both IKK1 and 
IKK2 (Devin et al., 2000; 2001). 
In addition, association of TRADD with 
TRAF2 can activate the Jun-(N)-terminal 
kinases (JNK1/2) via the N-terminal zinc-
finger domain of TRAF2. It has been 
demonstrated that activation of the up-
stream kinases ASK1 (apoptosis signal-
related kinase) and the mitogen-activated 
kinases MKK4 and MKK7 are essential for 
TNF-mediated JNK1/2 activation (Liedtke 
et al., 2011), which phosphorylates and ac-
tivates transcriptional factor c-Jun and so 
regulates the expression of interleukins IL-2 
and IL-8 (Baud et al., 1999). As a possible 
result IL-2 and its soluble IL-2 recepor is an 
immune cell activator in chronic liver dis-
eases in humans by attracting non-classical 
CD14+ and CD16+ monocytes (Seidler et 
al., 2012). 
Recent studies highlighted new poten-
tial molecules for drug targeting related to 
NF-kappaB signaling. The molecule recep-
tor interacting protein 3 (RIP3) interacts 
with inflammatory pathways in hepato-
cytes, because it limits pro-inflammatory 
immune response by inhibiting caspase-8-
dependent activation of JNK1/2 (Vucur et 
al., 2013). RIPs can also directly interact 
with NEMO and mediate IKK activation, 
although the enzymatic activity of RIP is 
not required for this process (Zhang et al., 
2000; Zhu et al., 2007, Israel, 2006). The 
mechanism by which recruitment of the 
IKK-complex to the TNF receptor leads to 
IKK activation is not clear, but might in-
volve NEMO induced autophosphorylation 
of the IKK-complex. Moreover, ubiquitina-
tion of multiple factors that regulate the 
IKK-complex, like TRAF6/TAK1 or c-
IAP1, an inhibitor of apoptosis that is also 
part of the TNF receptor complex, modulate 
the activity of the NF-kappaB pathway 
(Yamamoto and Gaynor, 2004). 
Nemo and IKKs themselves have also 
NF-kappaB-independent functions, which 
seem to play a role in the regulation of cell 
death, carcinogenesis and inflammation 
(Karin et al., 2004). 
 
Consequences of NF-kappaB activation  
in the liver 
After cytokine-consolidation with a 
death receptor additional to the resulting 
apoptosis of the cell (e.g. liver cell), surviv-
al signals are simultaneously activated. In 
case of the TNF-R, this is provided by NF-
kappaB. This process is assumed to involve 
the transcriptional induction of various 
apoptotic suppressors (Liu et al., 1996). Ev-
idence that NF-kappaB governs critical an-
ti-apoptotic proteins comes from well-
described animal models. Injection of TNF 
into mice and addition of TNF to hepatic 
cells in culture resulted in activation of nu-
clear translocation and of DNA binding of 
NF-kappaB (Fitzgerald et al., 1995). More-
over, hepatocytes are resistant to apoptosis 
induced by TNF or LPS, a potent inductor 
for endogenous TNF in the liver, unless 
they are treated with inhibitors of transcrip-
tion of (anti-apoptotic) proteins like cyclo-
heximide or actinomycin D (Lehmann et 
al., 1987; Leist et al., 1994; 1997). Knock-
out mice lacking the p65 subunit of NF-
kappaB die between days E15 and E16 
post-coitum as a result of fetal hepatocyte 
apoptosis (Beg and Baltimore, 1996). This 
is caused by increased sensitivity towards 
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TNF, since TNF/p65 double-deficient mice 
are rescued from embryonic lethality (Doi 
et al., 1999). 
Interestingly, IKK subunits in TNF-
mediated liver apoptosis have also differen-
tial functions. Genetic experiments have 
highlighted that mice lacking IKK1 die 
shortly after birth and display a phenotype 
marked by thickening of skin and limb as 
well as skeletal defects (Hu et al., 1999, 
Takeda et al., 1999). IKK2-deficient mice 
die in utero approximately at embryonic 
day 12.5 as a result of massive apoptosis in 
the liver, and fibroblasts from these mice 
show no activation of NF-kappaB in re-
sponse to TNF (Li et al., 1999a; 1999b, 
Tanaka et al., 1999). However, deletion of 
IKK/NEMO causes spontaneous progres-
sion of TNF-mediated chronic hepatitis to 
HCC, while this deletion of IKK/NEMO in 
TNFR1 knockout mice decreased apoptotic 
cell death, liver-fibrosis and infiltration of 
immune cells (Cubero et al., 2013; Schnei-
der et al., 2012; Rudolph et al., 2000). 
Therefore, at least during embryogenesis, 
IKK2 and NEMO appear to be the critical 
subunits for NF-kappaB activation and pro-
tection of liver cells from proinflammatory 
cytokines like TNF. 
IKK subunits in the adult animal and its 
role during TNFR1 activation are less well 
understood. Conditional knockout mice 
based on the cre/loxP system have emerged 
as new powerful tools to study gene func-
tions in the adult animal in vivo (Luedde 
and Trautwein, 2006; Pasparakis et al., 
2006). It was shown that hepatocyte-
specific ablation of IKK2 does not lead to a 
strongly impaired activation of NF-kappaB 
or increased apoptosis after TNF stimula-
tion, probably because IKK1 homodimers 
can take over this function in the absence of 
IKK2 in the adult mouse (Luedde et al., 
2005). In contrast, conditional hepatocyte-
specific knockout of NEMO resulted in 
complete block of NF-kappaB activation 
and massive hepatocyte apoptosis, underlin-
ing that NEMO is the only irreplaceable 
IKK subunit for prevention of TNF mediat-
ed liver apoptosis (Beraza et al., 2007).  
Furthermore, TNF mediated activation 
of NF-kappaB seems to have, besides its 
anti-apoptotic function, also essential func-
tions in various models of experimental liv-
er injury. For instance, NF-kappaB DNA-
binding occurs quickly upon hepatic ische-
mia-reperfusion (I/R) injury (Zwacka et al., 
1998), but it has also long been unclear 
whether NF-kappaB dependent signaling 
withholds a protective or damaging role in 
I/R injury. It was shown that hepatocyte-
specific conditional knockout mice for 
IKK2 show a defect in NF-kappaB activa-
tion after I/R (Luedde et al., 2005). Inhibi-
tion of NF-kappaB activation in conditional 
IKK2-deficient mice protected from liver 
injury due to I/R (Luedde et al., 2005), thus 
underlining that, depending on the experi-
mental model, the NF-kappaB pathway 
does not serve as a survival pathway, but 
instead can aggravate hepatocyte death and 
liver damage. However, complete abolish-
ment of NF-kappaB activation in condition-
al NEMO-knockout mice resulted in mas-
sive hepatic inflammation and apoptosis af-
ter I/R injury (Beraza et al., 2007). 
 
CONCLUSIONS 
A growing number of studies have im-
plicated immune cells, cytokines and cyto-
kine-dependent pathways in the develop-
ment of liver failure, chronic liver disease, 
hepatic inflammation and liver fibrogenesis. 
Resident and infiltrating immune cells de-
pending on their differentiation, detectable 
by their cell-surface markers, have been 
linked to progression (especially Ly-6Chi 
expressing iMϕ) as well as regression of 
liver injury (e.g., Ly-6Clo iMϕ) (Baeck et 
al., 2012; 2013). On the other hand, paren-
chymal and non-parenchymal survival 
pathways like NF-kappaB withhold a pro-
tective function in many experimental liver 
disease models and thus are an attractive 
target for a pharmacological intervention 
(Karin et al., 2002). However, many exper-
imental models highlighted dual functions 
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of these key players, namely beneficial or 
adverse effects. For instance, blockage of 
monocyte infiltration into the liver limits 
disease progression in different murine 
models, but also negatively affect the reso-
lution of liver fibrosis (Duffield et al., 
2005). Thus, an inflammatory immune cell 
is not necessarily detrimental in any con-
text. Similarly, an inhibition of NF-B in 
the liver can have different outcomes de-
pending on the experimental model applied: 
protecting from apoptosis in a model of 
TNF-dependent cell death vs. aggravating 
cellular necrosis in a model of ische-
mia/reperfusion injury (Luedde and 
Trautwein, 2006). Thus, a ‘survival’ path-
way is not necessarily protective in any 
context. Dissecting the cellular and molecu-
lar inflammatory pathways during liver 
homeostasis and during liver injury will 
hopefully provide the basis for novel spe-
cific therapeutic approaches in the near fu-
ture. 
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